The phase III CheckMate -649 demonstrated that first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in the overall survival and progression-free survival of patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma compared to treatment with chemotherapy alone.
The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.
